^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FHVH-BCMA-T

    i
    Associations
    News

    Trials

    Company:
    National Cancer Institute
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma (NCT03338972)
    Phase 1
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    09/08/2023
    Initiation :
    11/29/2017
    Primary completion :
    05/03/2021
    Completion :
    03/22/2022
    SDC1
    |
    SDC1 expression
    |
    cyclophosphamide • fludarabine IV • FCARH143 • FHVH-BCMA-T • cyclophosphamide intravenous